Picture Twist Bioscience We Do DNA 650x100px

Document › Details

MorphoSys AG. (11/7/17). "Press Release: MorphoSys Announces Third Quarter 2017 Results". Planegg.

	Organisation	MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
	Group	MorphoSys (Group)
	Organisation 2	Janssen (Group)
	Group	Johnson & Johnson (JnJ) (Group)
	Product	Tremfya™
	Product 2	tafasitamab (MOR208 / XmAb5574)
	Person	Moroney, Simon E. (MorphoSys 1992–201908 CEO + Founder STEPPED DOWN 9/19)
	Person 2	Enzelberger, Markus (Versant Ventures 202003– EIR in Basel before MorphoSys 2002–202002)

Original document
accessed by [iito] on 2017-11-14

Record changed: 2023-06-05

Picture Twist Bioscience Biopharma Solutions Our Gold Standard 650x200px

More documents for MorphoSys (Group)

[1] MorphoSys AG. (5/3/23). "Press Release: MorphoSys AG Reports First Quarter 2023 Financial Results". Planegg....
[2] MorphoSys AG. (3/14/23). "Press Release: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer". Planegg....
[3] MorphoSys AG. (3/2/23). "Press Release: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs". Planegg....
[4] MorphoSys AG. (12/20/22). "Press Release: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023". Planegg....
[5] MorphoSys AG. (12/6/22). "Press Release: MorphoSys Out Licenses Pre-Clinical Oncology Program". Planegg....
[6] MorphoSys AG. (11/14/22). "Press Release: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease". Planegg....
[7] Roche. (11/14/22). "Press Release: Roche Provides Update on Phase III GRADUATE Programme Evaluating Gantenerumab in Early Alzheimer’s Disease". Basel....
[8] MorphoSys AG. (10/27/22). "Press Release: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis". Planegg....
[9] MorphoSys AG. (8/31/22). "Press Release: MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters". Planegg....
[10] MorphoSys AG. (6/14/22). "Press Release: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210". Planegg & South San Francisco, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]